SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-062301
Filing Date
2023-05-18
Accepted
2023-05-18 17:00:17
Documents
5
Period of Report
2023-06-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm232158-3_def14a.htm DEF 14A 793216
2 GRAPHIC lg_protalix-4c.jpg GRAPHIC 22515
3 GRAPHIC sg_eyalrubin-bw.jpg GRAPHIC 10220
4 GRAPHIC px_protalixproxy1pg01-bwlr.jpg GRAPHIC 536609
5 GRAPHIC px_protalixproxy1pg02-bwlr.jpg GRAPHIC 676377
  Complete submission text file 0001104659-23-062301.txt   2330778
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 23936914
SIC: 2836 Biological Products, (No Diagnostic Substances)